Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

US suspends risky disease research

Government to cease funding gain-of-function studies that make viruses more dangerous, pending a safety assessment.

Outbreaks of influenza have prompted research into strains with pandemic potential. Credit: ChinaFotoPress/Getty

The US government surprised many researchers on 17 October when it announced that it will temporarily stop funding new research that makes certain viruses more deadly or transmissible. The White House Office of Science and Technology Policy is also asking researchers who conduct such ‘gain-of-function’ experiments on influenza, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) to stop their work until a risk assessment is completed — leaving many unsure of how to proceed.

Nobel for microscopy that reveals inner world of cells World's oldest art found in Indonesian cave Gravity rivals join forces to nail down Big G

“I think it’s really excellent news,” says Marc Lipsitch, an epidemiologist at the Harvard School of Public Health in Boston, Massachusetts, who has long called for more oversight for gain-of-function research. “I think it’s common sense to deliberate before you act.”

Critics of such work argue that it is unnecessarily dangerous and risks accidentally releasing viruses with pandemic potential — such as an engineered H5N1 influenza virus that easily spreads between ferrets breathing the same air1,2. In 2012, such concerns prompted a global group of flu researchers to halt gain-of-function experiments for a year (see Naturehttp://doi.org/wgx;2012). The debate reignited in July, after a series of lab accidents involving mishandled pathogens at the US Centers for Disease Control and Prevention in Atlanta, Georgia.

The White House’s abrupt move seems to be a response to renewed lobbying by gain-of-function critics who wanted such work suspended and others who sought to evaluate its risks and benefits without disrupting existing research.

Arturo Casadevall, a microbiologist at the Albert Einstein College of Medicine in New York City, calls the plan “a knee-jerk reaction”. “There is really no evidence that these experiments are in fact such high risk,” he says. “A lot of them are being done by very respectable labs, with lots of precautions in place.”

Some researchers are confused by the moratorium’s wording. Viruses are always mutating, and Casadevall says that it is difficult to determine how much mutation deliberately created by scientists might be “reasonably anticipated” to make a virus more dangerous — the point at which the White House states research must stop. The government says that this point will be determined for individual grants in discussions between funding officers and researchers.

One of the most prominent laboratories conducting gain-of-function studies is run by Yoshihiro Kawaoka, a flu researcher at the University of Wisconsin–Madison. In 2012, Kawaoka published a controversial paper1 reporting airborne transmission of engineered H5N1 flu between ferrets. He has since created an H1N1 flu virus using genes similar to those from the 1918 pandemic strain3, to show how such a dangerous flu could emerge. The engineered H1N1 was transmissible in mammals and much more harmful than the natural strain.

Kawaoka says that he plans to comply with the White House directive to halt current research once he understands which of his projects it affects. “I hope that the issues can be discussed openly and constructively so that important research will not be delayed indefinitely,” he says.

But it seems that the freeze could be lengthy. The White House says that it will wait for recommendations from the US National Science Advisory Board for Biosecurity (NSABB) and the National Research Council before deciding whether and how to lift the ban. The groups are expected to finish their work within a year. As Nature went to press, the NSABB was set to convene on 22 October, its first meeting in two years. Lipsitch, who will speak at the event, says that he will advocate for the development of an objective risk-assessment tool to evaluate individual research projects. In particular, he says, decision-makers should consider whether a gain-of-function study makes a contribution to a public-health goal, such as the prevention and treatment of flu, that could justify both the risk and the use of money that could be spent on safer research.

“There clearly are going to be instances where gain-of-function research is necessary and appropriate, and there are others where the opposite applies,” says Ian Lipkin, a virologist at Columbia University in New York City. The need to understand the ongoing Ebola outbreak in West Africa and control its spread, for instance, emphasizes the importance of infectious-disease research — as well as the regulation of such work, Lipkin says. Although public worry about Ebola being transferred through the air is unfounded, researchers could make a case for the need to determine how the virus could evolve in nature by engineering a more dangerous version in the lab. “I think we should have some sort of guidelines in place before such experiments are even proposed,” says Lipkin. Yet Ebola is not included in the White House’s research-funding ban, and a spokesperson says that there are no plans to include it on the list.

One thing is certain, says Casadevall: the NSABB meeting is certain to see heated debate as scientists from all sides convene. “I hope they have enough room,” he adds.

References

  1. Imai, M. et al. Nature 486, 420–428 (2012).

    ADS  CAS  Article  Google Scholar 

  2. Herfst, S. et al. Science 336, 1534–1541 (2012).

    ADS  CAS  Article  Google Scholar 

  3. Watanabe, T. et al. Cell Host Microbe 15, 692–705 (2014).

    CAS  Article  Google Scholar 

Download references

Authors

Additional information

See Editorial page 403

Related links

Related links

Related links in Nature Research

A ripe time for gaining ground 2014-Oct-22

Safety lapses in US government labs spark debate 2014-Jul-16

Risks of flu work underrated 2014-Jul-01

Scientists call for urgent talks on mutant-flu research in Europe 2013-Dec-20

Controversial H5N1 influenza work likely to resume 2012-Dec-19

Call to censor flu studies draws fire 2012-Jan-03

Blog post: US announces rules for potential bioterror agents

Related external links

White House announcement

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Reardon, S. US suspends risky disease research. Nature 514, 411–412 (2014). https://doi.org/10.1038/514411a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/514411a

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing